Literature DB >> 15217831

Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications.

Kiarash Kojouri1, Sara K Vesely, Deirdra R Terrell, James N George.   

Abstract

Splenectomy has been a standard treatment for adult patients with idiopathic thrombocytopenic purpura (ITP) for more than 50 years. However, the durability of responses, the ability to predict who will respond, and the frequency of surgical complications with splenectomy all remain uncertain. To better interpret current knowledge we systematically identified and reviewed all 135 case series, 1966 to 2004, that described 15 or more consecutive patients who had splenectomy for ITP and that had data for 1 of these 3 outcomes. Complete response was defined as a normal platelet count following splenectomy and for the duration of follow-up with no additional treatment. Forty-seven case series reported complete response in 1731 (66%) of 2623 adult patients with follow-up for 1 to 153 months; complete response rates did not correlate with duration of follow-up (r = -0.103, P = .49). None of 12 preoperative characteristics that have been reported consistently predicted response to splenectomy. Mortality was 1.0% (48 of 4955 patients) with laparotomy and 0.2% (3 of 1301 patients) with laparoscopy. Complication rates were 12.9% (318 of 2465) with laparotomy and 9.6% (88 of 921 patients) with laparoscopic splenectomy. Although the risk of surgery is an important consideration, splenectomy provides a high frequency of durable responses for adult patients with ITP.

Entities:  

Mesh:

Year:  2004        PMID: 15217831     DOI: 10.1182/blood-2004-03-1168

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  132 in total

Review 1.  Immune thrombocytopenia: no longer 'idiopathic'.

Authors:  Keith McCrae
Journal:  Cleve Clin J Med       Date:  2011-06       Impact factor: 2.321

Review 2.  Piecing together the humoral and cellular mechanisms of immune thrombocytopenia.

Authors:  Lisa J Toltl; Ishac Nazi; Reza Jafari; Donald M Arnold
Journal:  Semin Thromb Hemost       Date:  2011-11-18       Impact factor: 4.180

Review 3.  Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters.

Authors:  Lisa J Toltl; Donald M Arnold
Journal:  Br J Haematol       Date:  2010-11-18       Impact factor: 6.998

4.  Recent advances in the treatment of chronic refractory immune thrombocytopenic purpura.

Authors:  Kiarash Kojouri; James N George
Journal:  Int J Hematol       Date:  2005-02       Impact factor: 2.490

5.  Laparoscopic surgery of the spleen.

Authors:  Eduardo M Targarona; Manuel Trias
Journal:  World J Surg       Date:  2007-06       Impact factor: 3.352

6.  Long-term outcomes of laparoscopic versus open splenectomy for immune thrombocytopenia.

Authors:  Kazuhiro Tada; Masayuki Ohta; Kunihiro Saga; Hiroomi Takayama; Teijiro Hirashita; Yuichi Endo; Hiroki Uchida; Yukio Iwashita; Masafumi Inomata
Journal:  Surg Today       Date:  2017-07-19       Impact factor: 2.549

Review 7.  Laparoscopic Splenectomy for Benign Hematological Disorders in Adults: A Systematic Review.

Authors:  Demetrios Moris; Nikoletta Dimitriou; John Griniatsos
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

Review 8.  Laparoscopic splenectomy for primary immune thrombocytopenia: Current status and challenges.

Authors:  Dong Zheng; Chen-Song Huang; Shao-Bin Huang; Chao-Xu Zheng
Journal:  World J Gastrointest Endosc       Date:  2016-09-16

9.  Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists.

Authors:  Bahareh Ghadaki; Ishac Nazi; John G Kelton; Donald M Arnold
Journal:  Transfusion       Date:  2013-03-03       Impact factor: 3.157

10.  B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells.

Authors:  Matthieu Mahévas; Pauline Patin; François Huetz; Marc Descatoire; Nicolas Cagnard; Christine Bole-Feysot; Simon Le Gallou; Mehdi Khellaf; Olivier Fain; David Boutboul; Lionel Galicier; Mikael Ebbo; Olivier Lambotte; Mohamed Hamidou; Philippe Bierling; Bertrand Godeau; Marc Michel; Jean-Claude Weill; Claude-Agnès Reynaud
Journal:  J Clin Invest       Date:  2012-12-17       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.